{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:09:42Z","timestamp":1772118582782,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Brentuximab vedotin (BV)\u2010bendamustine (90 or 120\u00a0mg\/m2 day 1 and 2) every 28\u00a0days is an effective treatment for relapsed\/refractory Hodgkin lymphoma (R\/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single\u2010center analysis of 44 patients with R\/R HL treated with one\u2010day BV\u2010bendamustine (120\u00a0mg\/m2) every 21\u00a0days. Sixteen percent of patients were\u00a0\u2265\u00a060\u00a0years old (yo). Seventy\u2010three percent of patients received total number of cycles without interruption nor adaptation. No patient \u2265\u00a070 yo required treatment interruption. Dose adjustment was necessary for 18% of patients. Infusion\u2010related reaction (36%) occurred always at cycle 2 and was the only cause of treatment interruption. One febrile neutropenia, one non\u2010documented septic shock, one pyelonephritis on transplanted kidney and one COVID complicated by cytopenias were reported. Sixteen percent patients presented a peripheral sensory neuropathy, 7% and 4% respectively grade 3\u20134 neutropenia and thrombocytopenia. Overall response was 84%, with 73% of complete remission. Median progression\u2010free survival was of 19.8\u00a0months (95% CI 13.1\u2010NR) and median overall survival was not reached with a median follow\u2010up of 31\u00a0months. We suggest that one\u2010day BV\u2010bendamustine (120\u00a0mg\/m2) ever 21\u00a0days is a safe and feasible treatment for R\/R HL especially for elderly patients.<\/jats:p>","DOI":"10.1002\/hon.70031","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T16:14:38Z","timestamp":1735402478000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["One\u2010Day Brentuximab\u2013Bendamustine (120\u00a0mg\/m2) Every 21\u00a0Days is a Feasible, Safe and Effective Treatment for Relapsed\/Refractory Hodgkin Lymphoma"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6309-0928","authenticated-orcid":false,"given":"H.","family":"Moatti","sequence":"first","affiliation":[{"name":"Service d\u2019H\u00e9matologie Centre Hospitalier Annecy Genevois  Epagny\u2010Metz\u2010Tessy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Brice","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9mato\u2010Oncologie APHP H\u00f4pital St Louis  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u2010C.","family":"Laroque","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie Centre Hospitalier de Brive  Brive\u2010la\u2010Gaillarde France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Di Blasi","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9mato\u2010Oncologie APHP H\u00f4pital St Louis  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wencel","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie Clinique APHP H\u00f4pital Henri\u2010Mondor  Cr\u00e9teil France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Delory","sequence":"additional","affiliation":[{"name":"Service de Direction de la Recherche Clinique Centre Hospitalier Annecy Genevois  Epagny\u2010Metz\u2010Tessy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Madelaine\u2010Chambrin","sequence":"additional","affiliation":[{"name":"Pharmacie APHP H\u00f4pital St Louis  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schmidt\u2010Hieber","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department Jena University Hospital  Jena Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Ravdan","sequence":"additional","affiliation":[{"name":"Clinique du Pont de S\u00e8vres  Boulogne\u2010Billancourt France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9mato\u2010Oncologie APHP H\u00f4pital St Louis  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-9464","authenticated-orcid":false,"given":"L.","family":"Renaud","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019H\u00e9matologie Institut Gustave Roussy Universit\u00e9 Paris\u2010Saclay  Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01777"},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf221"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243238"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124784"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201011\u2010815183"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14449"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010187466"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(17)30912\u20109"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201006\u2010787200"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18215"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T15:22:14Z","timestamp":1738164134000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/hon.70031"],"URL":"https:\/\/doi.org\/10.1002\/hon.70031","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.70031\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70031\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70031\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"2024-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70031"}}